Cantourage, a Berlin-based pharmaceutical company, is experiencing remarkable growth due to the rising demand for medical cannabis in Germany. The company is listed on the Frankfurt Stock Exchange under the ticker symbol ‘HIGH’.
CEO Philip Schetter recently showcased the company’s operations at a secure facility in Bavaria, revealing a substantial stock of cannabis secured behind a formidable 75-centimeter (30-inch) thick steel door. “Better safe than sorry,” Schetter remarked, highlighting the importance of security in the cannabis industry.
The German medical cannabis market has expanded significantly since the country legalized the use of cannabis for medical purposes in 2017. According to recent data, the number of patients authorized to use medical cannabis has surged, with over 100,000 patients currently registered with prescriptions. This shift has prompted pharmaceutical companies, like Cantourage, to scale up production to meet the increasing demand.
Cantourage specializes in producing and distributing cannabis-based medicinal products. The firm focuses on quality and compliance, ensuring its products meet strict regulations set forth by the German government. As a result, the company has positioned itself as a reliable supplier within the medical cannabis sector.
The growth of Cantourage is mirrored by the overall trajectory of the German cannabis industry. Reports indicate that the market is expected to reach approximately €1 billion by 2025, driven by both patient demand and a broader acceptance of cannabis as a legitimate treatment option.
As the medical cannabis landscape continues to evolve, Cantourage remains committed to expanding its operations and increasing its presence in the market. With the company’s innovative approach and adherence to regulatory standards, it aims to contribute to the ongoing development of the cannabis industry in Germany.
English 
Spanish 
German 
Czech